Immorna Therapeutics, a biotech company specializing in mRNA-based vaccines and located in Hangzhou, has announced that it has received approval from the U.S. Food and Drug Administration (FDA) to conduct a Phase I/II clinical study for its self-replicating RNA cancer therapy, JCXH-211-IV (intravenous injection). JCXH-211-IV is a potential first-in-class drug globally, featuring a dual anti-tumor mechanism that leverages the innate immune activation ability of self-replicating RNA (srRNA) and the anti-tumor immune regulatory efficacy provided by the expression of IL-12.
The company is also developing JCXH-211-IT (intratumoral injection), which shares the same mechanism as JCXH-211-IV. JCXH-211-IT has shown promising results in terms of safety, tolerability, and significant anti-tumor activity in a Phase I study.- Flcube.com
